Predicting Prognosis in Non-Small Cell Lung Cancer Using Number of Nodal Stations
The number of involved nodal stations has the potential to provide a more accurate prognosis in patients with resected non-small cell lung cancer.
Non-Small Cell Lung Cancer
Tiragolumab Gets Breakthrough Therapy Status for PD-L1-High NSCLC
Tiragolumab is a monoclonal antibody that works by binding to TIGIT, a protein receptor on immune cells, and blocking its interaction with the poliovirus receptor.
Lorlatinib Under Review for Previously Untreated ALK-Positive NSCLC
The sNDA is supported by data from the phase 3 CROWN study comparing lorlatinib to Xalkori in 296 adults with advanced ALK-positive NSCLC.
New Dosing Option Approved for Durvalumab in NSCLC
The approval was based on data from several clinical trials, including the phase 3 PACIFIC trial and the phase 3 CASPIAN trial.
Cemiplimab Granted Priority Review for Advanced NSCLC
Topline results from the trial showed that compared with chemotherapy, treatment with cemiplimab-rwlc reduced the risk of death by 32% in the overall trial population.
Tepotinib Yields High Partial Response Rates in NSCLC With MET Alterations
The MET alteration occurs in 3% to 4% of patients with the condition.
Patient Access to Lung Cancer Treatment Guidelines May Improve Quality of Care
Use of cancer treatment guidelines is not in conflict with shared decision-making; therefore, increasing patients’ access to guidelines may improve the quality of oncologic care.
Cannabinoid Receptor CB2 Is a Potential Prognostic Biomarker in NSCLC
Overexpression of cannabinoid receptor CB2 may be a prognostic biomarker for NSCLC adenocarcinomas.
Tepotinib Gets Priority Review for Metastatic NSCLC With METex14 Skipping Mutation
The FDA has granted Priority Review to tepotinib for metastatic NSCLC whose tumors have a mutation that leads to METex14 skipping.
Racial Disparities Seen in PET/CT Imaging for Lung Cancer
Black and Hispanic patients are less likely to receive recommended imaging at time of diagnosis of NSCLC.
-
Loading...
-
Loading...
Next post in Lung Cancer
